September 2024 SEHK Growth Companies With High Insider Ownership

As global markets grapple with economic uncertainties, the Hong Kong market has not been immune to these fluctuations, reflecting broader concerns about growth and stability. Despite this backdrop, certain growth companies with high insider ownership have managed to capture investor interest due to their potential for sustained performance and alignment of interests between management and shareholders. In such a volatile environment, stocks that demonstrate robust growth prospects coupled with significant insider ownership can be particularly appealing. This combination often indicates strong confidence from those closest to the company's operations and strategic direction.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name	Insider Ownership	Earnings Growth
Laopu Gold (SEHK:6181)	36.4%	34.7%
Akeso (SEHK:9926)	20.5%	55.0%
Pacific Textiles Holdings (SEHK:1382)	11.2%	37.7%
Fenbi (SEHK:2469)	31.2%	22.4%
Zylox-Tonbridge Medical Technology (SEHK:2190)	18.7%	69.8%
Adicon Holdings (SEHK:9860)	22.4%	31.2%
Zhejiang Leapmotor Technology (SEHK:9863)	14.6%	78.9%
DPC Dash (SEHK:1405)	38.2%	104.2%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	13.9%	109.2%
Beijing Airdoc Technology (SEHK:2251)	28.6%	93.4%

Click here to see the full list of 47 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

ESR Group (SEHK:1821)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ESR Group Limited, with a market cap of HK$52.64 billion, engages in logistics real estate development, leasing, and management across Hong Kong, China, Japan, South Korea, Australia, New Zealand, Southeast Asia, India, Europe and internationally.

Operations: The company's revenue segments include Fund Management ($627.98 million) and New Economy Development ($113.33 million).

Insider Ownership: 13%

Earnings Growth Forecast: 78.9% p.a.

ESR Group, a growth company with high insider ownership in Hong Kong, is forecast to grow earnings by 78.86% annually and become profitable within three years. Despite trading at 79.5% below its estimated fair value, recent guidance indicates a net loss of US$210 million for H1 2024 due to non-cash asset revaluations and market conditions. Leadership changes include Brett Harold Krause as interim chairman following Jeffrey Perlman's departure to Warburg Pincus.

• Click to explore a detailed breakdown of our findings in ESR Group's earnings growth report.
• Insights from our recent valuation report point to the potential overvaluation of ESR Group shares in the market.

Meituan (SEHK:3690)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meituan operates as a technology retail company in the People’s Republic of China with a market cap of approximately HK$724.49 billion.

Operations: The company's revenue segments include New Initiatives, generating CN¥77.56 billion, and Core Local Commerce, contributing CN¥228.13 billion.

Insider Ownership: 11.6%

Earnings Growth Forecast: 25.8% p.a.

Meituan's recent earnings report for H1 2024 showed substantial growth, with sales rising to CNY 155.53 billion and net income doubling to CNY 16.72 billion. The company also announced a share repurchase program worth $1 billion, reflecting confidence in its future prospects. Despite significant insider selling over the past three months, Meituan's earnings are forecast to grow by 25.8% annually, outpacing the Hong Kong market average of 11.7%.

• Get an in-depth perspective on Meituan's performance by reading our analyst estimates report here.
• Insights from our recent valuation report point to the potential undervaluation of Meituan shares in the market.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$48.31 billion.

Operations: The company generates CN¥1.87 billion from its research, development, production, and sale of biopharmaceutical products.

Insider Ownership: 20.5%

Earnings Growth Forecast: 55.0% p.a.

Akeso is a growth company with high insider ownership, forecasted to achieve 32.7% annual revenue growth and become profitable within three years. Recent earnings showed a significant drop in revenue to CNY 1.02 billion and a net loss of CNY 238.59 million for H1 2024, but the company continues advancing its innovative drug pipeline, including ivonescimab's priority review for NSCLC treatment in China and ongoing global clinical trials, highlighting strong potential despite recent financial setbacks.

• Unlock comprehensive insights into our analysis of Akeso stock in this growth report.
• The valuation report we've compiled suggests that Akeso's current price could be inflated.

Where To Now?

• Gain an insight into the universe of 47 Fast Growing SEHK Companies With High Insider Ownership by clicking here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com